Patient characteristics in MAC and RIC/NMA groups
| Variable . | MAC (n = 978) . | RIC/NMA (n = 777) . | P . |
|---|---|---|---|
| Male sex, n (%) | 489 (50) | 448 (58) | .0 |
| Age, median (range), y | 52 (40-71) | 61 (41-81) | <.001 |
| 40-49 | 404 (41) | 87 (11) | <.001 |
| 50-59 | 451 (46) | 237 (31) | |
| ≥60 | 123 (13) | 453 (58) | |
| Performance score, n (%) | .269 | ||
| <90 | 300 (31) | 258 (33) | |
| ≥90 | 662 (68) | 502 (65) | |
| Missing | 16 (2) | 17 (2) | |
| HCT–comorbidity index, n (%) | .173 | ||
| 0 | 268 (27) | 190 (24) | |
| 1-2 | 221 (23) | 179 (23) | |
| ≥3 | 263 (27) | 236 (30) | |
| Not collected (before 2007) | 216 (22) | 159 (20) | |
| Missing | 10 (1) | 13 (2) | |
| Presence of previous MDS, yes, n (%) | 155 (16) | 173 (22) | .003 |
| Cytogenetic risk, n (%) | .31 | ||
| Favorable | 26 (3) | 20 (3) | |
| Intermediate | 608 (62) | 469 (60) | |
| Poor | 285 (29) | 232 (30) | |
| Not tested | 22 (2) | 12 (2) | |
| Missing | 37 (4) | 44 (6) | |
| Time from diagnosis to AlloHCT, median (range), mo | 5 (2-12) | 5 (<1-13) | <.001 |
| Donor/recipient HLA match, n (%) | <.001 | ||
| Cord blood | 88 (9) | 169 (22) | |
| Matched related donor | 381 (39) | 216 (28) | |
| Well-matched unrelated | 391 (40) | 299 (38) | |
| Partially matched unrelated | 94 (10) | 66 (8) | |
| Mismatched unrelated | 4 (< 1) | 3 (< 1) | |
| Unrelated (HLA match information missing) | 20 (2) | 24 (3) | |
| Graft type, n (%) | <.001 | ||
| Bone marrow | 136 (14) | 55 (7) | |
| Peripheral blood | 754 (77) | 553 (71) | |
| Cord blood | 88 (9) | 169 (22) | |
| GVHD prophylaxis, n (%) | <.001 | ||
| TAC/CsA + MTX ± others (not MMF) | 657 (67) | 290 (37) | |
| TAC/CsA + MMF ± others (not MTX) | 202 (21) | 378 (49) | |
| TAC/CsA ± others (not MMF/MTX) | 96 (10) | 70 (9) | |
| Other GVHD prophylaxis* | 23 (2) | 39 (5) | |
| ATG/alemtuzumab as conditioning or GVHD prophylaxis, n (%) | <.001 | ||
| ATG alone | 236 (24) | 276 (36) | |
| Alemtuzumab alone | 6 (<1) | 29 (4) | |
| No ATG or alemtuzumab | 736 (75) | 472 (61) | |
| Donor-recipient sex match, n (%) | .01 | ||
| Male-male | 321 (33) | 294 (38) | |
| Male-female | 295 (30) | 181 (23) | |
| Female-male | 168 (17) | 154 (20) | |
| Female-female | 193 (20) | 148 (19) | |
| Missing | 1 (< 1) | 0 | |
| Donor-recipient CMV status, n (%) | .44 | ||
| +/+ | 272 (28) | 189 (24) | |
| +/− | 92 (9) | 76 (10) | |
| −/+ | 332 (34) | 300 (39) | |
| −/− | 269 (28) | 200 (26) | |
| Missing | 13 (1) | 12 (2) | |
| Total body irradiation, yes, n (%) | 300 (31) | 312 (40) | <.001 |
| Planned G-CSF, GM-CSF use, yes, n (%) | 363 (37) | 293 (38) | .29 |
| History of clinically significant fungal infection, yes, n (%) | 115 (12) | 102 (13) | .67 |
| Year of transplant, n (%) | <.001 | ||
| 2006-2007 | 216 (22) | 159 (20) | |
| 2008-2009 | 336 (34) | 259 (33) | |
| 2010-2011 | 236 (24) | 143 (18) | |
| 2012-2013 | 190 (19) | 216 (28) |
| Variable . | MAC (n = 978) . | RIC/NMA (n = 777) . | P . |
|---|---|---|---|
| Male sex, n (%) | 489 (50) | 448 (58) | .0 |
| Age, median (range), y | 52 (40-71) | 61 (41-81) | <.001 |
| 40-49 | 404 (41) | 87 (11) | <.001 |
| 50-59 | 451 (46) | 237 (31) | |
| ≥60 | 123 (13) | 453 (58) | |
| Performance score, n (%) | .269 | ||
| <90 | 300 (31) | 258 (33) | |
| ≥90 | 662 (68) | 502 (65) | |
| Missing | 16 (2) | 17 (2) | |
| HCT–comorbidity index, n (%) | .173 | ||
| 0 | 268 (27) | 190 (24) | |
| 1-2 | 221 (23) | 179 (23) | |
| ≥3 | 263 (27) | 236 (30) | |
| Not collected (before 2007) | 216 (22) | 159 (20) | |
| Missing | 10 (1) | 13 (2) | |
| Presence of previous MDS, yes, n (%) | 155 (16) | 173 (22) | .003 |
| Cytogenetic risk, n (%) | .31 | ||
| Favorable | 26 (3) | 20 (3) | |
| Intermediate | 608 (62) | 469 (60) | |
| Poor | 285 (29) | 232 (30) | |
| Not tested | 22 (2) | 12 (2) | |
| Missing | 37 (4) | 44 (6) | |
| Time from diagnosis to AlloHCT, median (range), mo | 5 (2-12) | 5 (<1-13) | <.001 |
| Donor/recipient HLA match, n (%) | <.001 | ||
| Cord blood | 88 (9) | 169 (22) | |
| Matched related donor | 381 (39) | 216 (28) | |
| Well-matched unrelated | 391 (40) | 299 (38) | |
| Partially matched unrelated | 94 (10) | 66 (8) | |
| Mismatched unrelated | 4 (< 1) | 3 (< 1) | |
| Unrelated (HLA match information missing) | 20 (2) | 24 (3) | |
| Graft type, n (%) | <.001 | ||
| Bone marrow | 136 (14) | 55 (7) | |
| Peripheral blood | 754 (77) | 553 (71) | |
| Cord blood | 88 (9) | 169 (22) | |
| GVHD prophylaxis, n (%) | <.001 | ||
| TAC/CsA + MTX ± others (not MMF) | 657 (67) | 290 (37) | |
| TAC/CsA + MMF ± others (not MTX) | 202 (21) | 378 (49) | |
| TAC/CsA ± others (not MMF/MTX) | 96 (10) | 70 (9) | |
| Other GVHD prophylaxis* | 23 (2) | 39 (5) | |
| ATG/alemtuzumab as conditioning or GVHD prophylaxis, n (%) | <.001 | ||
| ATG alone | 236 (24) | 276 (36) | |
| Alemtuzumab alone | 6 (<1) | 29 (4) | |
| No ATG or alemtuzumab | 736 (75) | 472 (61) | |
| Donor-recipient sex match, n (%) | .01 | ||
| Male-male | 321 (33) | 294 (38) | |
| Male-female | 295 (30) | 181 (23) | |
| Female-male | 168 (17) | 154 (20) | |
| Female-female | 193 (20) | 148 (19) | |
| Missing | 1 (< 1) | 0 | |
| Donor-recipient CMV status, n (%) | .44 | ||
| +/+ | 272 (28) | 189 (24) | |
| +/− | 92 (9) | 76 (10) | |
| −/+ | 332 (34) | 300 (39) | |
| −/− | 269 (28) | 200 (26) | |
| Missing | 13 (1) | 12 (2) | |
| Total body irradiation, yes, n (%) | 300 (31) | 312 (40) | <.001 |
| Planned G-CSF, GM-CSF use, yes, n (%) | 363 (37) | 293 (38) | .29 |
| History of clinically significant fungal infection, yes, n (%) | 115 (12) | 102 (13) | .67 |
| Year of transplant, n (%) | <.001 | ||
| 2006-2007 | 216 (22) | 159 (20) | |
| 2008-2009 | 336 (34) | 259 (33) | |
| 2010-2011 | 236 (24) | 143 (18) | |
| 2012-2013 | 190 (19) | 216 (28) |
CsA, cyclosporine; Cy, cyclophosphamide; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-monocyte colony-stimulating factor; MMF, mycophenolate mofetil; MTX, methotrexate; Tac, tacrolimus.
Other GVHD prophylaxis: MMF ± others (MAC = 2, RIC/NMA = 6), sirolimus ± others (MAC = 4, RIC/NMA = 9), others (MAC = 17, RIC/NMA = 24).